四逆散不同配伍干预实验性溃疡性结肠炎的效用和机制研究
|
摘要
目的:通过实验,验证四逆散及其不同配伍干预实验性溃疡性结肠炎(ulcerative colitis,UC)的效用,探讨四逆散不同配伍干预实验性UC的机制。
材料与方法:
1四逆散不同配伍干预实验性UC的效用研究
将实验大鼠分为14组,采用免疫法造模,以实验大鼠一般状况、结肠组织大体情况、结肠组织病理变化,胸腺指数、脾脏指数和结肠组织NF-κB作为观察与检测指标,用Q-PCR检测核因子-κB(nuclear factor-kappa B,NF-κB)在组织的基因表达,用免疫组化法检测NF-κB的活性。
2四逆散干预实验性UC的机制研究
在“四逆散不同配伍干预实验性UC的效用研究”的基础上,将实验动物分为5组,采用免疫法造模,以实验大鼠结肠组织大体情况、结肠组织病理变化和白细胞介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-4(interleukin-4,IL-4)、白细胞介素-10(interleukin-10,IL-10)作为观察与检测指标,用Q-PCR检测上述细胞因子在组织的基因表达,用ELISA法检测细胞因子活性。
结果:
1四逆散不同配伍干预实验性UC的效用研究
1.1四逆散不同配伍对实验性UC大鼠一般状况的影响
造模第l4天,大鼠多出现食量减少、拱背、聚堆、懒动;第21天,均出现饮食明显减少,稀便、毛发不泽,拱背、聚堆、懒动。各给药组造模大鼠上述症状有不同程度改善。正常组大鼠饮食、大小便、活动正常。给药前后正常组实验大鼠体重平均增长54%,而其他各组实验大鼠体重平均增长范围在32%～38%。
1.2四逆散不同配伍对实验性UC大鼠结肠组织损伤的影响
肉眼观察,模型组大鼠病变结肠肠壁增厚,肠黏膜糜烂,黏膜表面弥漫性充血、水肿,可见出血点和溃疡。各药物治疗组大鼠结肠黏膜表现不同程度充血、水肿,可见轻度糜烂和溃疡。结肠组织损伤程度评分结果显示,造模组大鼠的结肠损伤程度明显高于正常组(P<0.05)。与模型组比较,各药组大鼠的结肠损伤程度显著降低。
光镜下观察,模型组黏膜表面可见溃疡形成,个别深达肌层,炎症反应较重,有充血、糜烂,中性粒细胞浸润,黏膜上皮部分缺失,局部固有层腺体减少,黏膜下层血管增生,黏膜肌层不明显。其余各组均有不同程度的病变。结肠病理组织学评分结果显示,造模组大鼠的结肠病理组织学评分结果明显高于正常组(P<0.05)。与模型组比较,芍甘组和枳甘组无明显差异,其余各组显著降低(P<0.05)。
1.3四逆散不同配伍对实验性UC大鼠胸腺指数与脾脏指数的影响
造模后,模型组和柴芍组大鼠胸腺指数显著低于正常组,以柴芍组降低最为显著(P<0.05),其余各组与正常组无显著性差异;与模型组比较,对照组、四逆散组、柴芍甘组、芍枳甘组、柴芍组、柴甘组、芍甘组和枳甘组大鼠胸腺指数均存在显著差异。造模后大鼠脾脏指数均显著高于正常组(P<0.05);与模型组相比,对照组、四逆散组和柴枳甘组的脾脏指数显著增高(P<0.05)。
1.4四逆散不同配伍对实验性UC大鼠结肠组织NF-κB基因表达及活性的影响
模型组实验大鼠结肠黏膜NF-κB mRNA表达水平明显高于正常组(P<0.05);各药物组实验大鼠结肠黏膜NF-κB mRNA表达水平与模型组比较均存在显著性差异,其中,枳甘组显著高于模型组(P<0.05)。
模型组实验大鼠结肠黏膜NF-κB活性明显高于正常组(P<0.05);四逆散组与正常组比较,无显著差异;除柴甘组和枳甘组外,其余各药物组均显著低于模型组(P<0.05);与四逆散组比较,各药物组显著高于四逆散组(P<0.05)。
2四逆散干预实验性UC的机制研究
2.1四逆散对实验性UC大鼠IL-1β的影响
模型组实验大鼠结肠黏膜IL-1βmRNA表达水平明显高于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著降低(P<0.05)。
模型组和四逆散组实验大鼠血清IL-1β含量明显高于正常组(P<0.05),而柴芍枳组和柴芍组与正常组比较无统计学意义;四逆散组与模型组比较无显著性差异;柴芍枳组和柴芍组显著低于模型组和四逆散组(P<0.05)。
2.2四逆散对实验性UC大鼠TNF-α的影响
模型组实验大鼠结肠黏膜TNF-αm RNA表达水平明显高于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著降低(P<0.05);柴芍枳组明显高于四逆散组(P<0.05),而柴芍组明显低于四逆散组(P<0.05)。与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清TNF-α的含量均明显高于正常组;与模型组比较,四逆散组、柴芍枳组和柴芍组显著降低(P<0.05)。
2.3四逆散对实验性UC大鼠IL-4的影响
模型组实验大鼠结肠黏膜IL-4 mRNA表达水平明显低于正常组(P<0.05);四逆散组和柴芍枳组与正常组比较无显著性差异,而柴芍组则显著高于正常组(P<0.05);与模型组比较,四逆散组、柴芍枳组和柴芍组均显著升高(P<0.05);柴芍枳组和柴芍组均显著高于四逆散组(P<0.05)。
与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清IL-4的含量均明显降低(P<0.05);给药后,柴芍枳组与模型组比较无显著性差异,而四逆散组和柴芍组大鼠明显高于模型组(P<0.05),其中,柴芍组明显低于四逆散组(P<0.05)。
2.4四逆散对实验性UC大鼠IL-10的影响
模型组实验大鼠结肠黏膜IL-10 mRNA表达水平明显低于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著升高(P<0.05)。
与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清IL-10的含量均明显降低(P<0.05);给药后,柴芍枳组与模型组比较无显著性差异,而四逆散组和柴芍组大鼠明显高于模型组(P<0.05),柴芍组明显低于四逆散组(P<0.05)。
结论:
四逆散能够干预实验性UC,其作用可能是通过刺激免疫器官分泌免疫细胞,抑制NF-κB的激活来实现的;四逆散对实验性UC作用以全方作用最为理想。
四逆散能够干预实验性UC,其作用机理可能为:①抑制促炎因子IL-1β的移行和TNF-α的分泌,促进抗炎因子IL-4和IL-10的分泌,调节促炎因子和抗炎因子之间的平衡,干预实验性UC;②降低实验性UC大鼠结肠黏膜NF-κB的表达水平,调控UC细胞因子网络。
Purpose:The study of utility and mechanism is the Sini powders and the different compatibilities in intervening experimental ulcerative colitis.
Material and method:
1 Study of Utility on the Sini Powders and the Different Compatibilities in Intervening Experimental Ulcerative Colitis
The experimental animals were divided into 14 groups and modeled with immunization. The states, colon organization and its pathological changes varying, thymus index, spleen index and activity of NF-κB of rats were treated as observation and measurement indicators. NF-κB mRNA was detected by Q-PCR technique. And it’s protein activity was detected by immunohistochemistry.
2 Study of Mechanism on the Sini Powders in Intervening Experimental Ulcerative Colitis Based on the first study, the experimental animals were divided into 5 groups and modeled with immunization. The states, colon organization and its pathological changes varying, IL-1β, TNF-α, IL-4, IL-10 of rats were treated as observation and measurement indicators. And we detected those cell factors mRNA with Q-PCR and activities with ELISA.
Results:
1 Study of Utility on the Sini Powders and the Different Compatibilities in Intervening Experimental Ulcerative Colitis
1.1 The states
Animalpatterns appeared diet reducedg, arch, polyethylene reactor and lazy action at the 14th day, and diet significantly reduced, diarrhea, hair dryed, arch, polyethylene reactor and lazy action at the 21st after modeling. Administrated orally, above symptoms the rats showed improvement with different degree.
The increasing healthy rats' weight was 54%, but the modeling rats’weight increased averagely the range within 32%～38% before and after drug administration.
1.2 Colon Organization and its Pathological Changes
With visualinspection, we found the intestinal wall thicken, mucous membrane erosion, suiface of mucous membrane diffuse congestion and edema of the rates colons of model group. And blutpunkte and ulcer cound be observed. But all treatment groups were improved inordinately. The experimental result showed the model group was significant difference with normal group (P<0.05). Compared with model group, the degrees of colonic injury of all drug groups were significantly lower (P<0.05).
Under light microscope, we observed there were ulceration, neutrophilicgranulocyte infiltration, congestion, erosion, epithelium deletion, lamina propria gland lessen, vessel hyperplasia of the rates colons of model group. The experimental result showed the model group was significant difference with normal group (P<0.05).Compared with model group, besides Chaishao group and Zhigan group, the rest groups were all significantly lower.
1.3 Thymus Index and Spleen Index
The different compatibilities can improve significantly thymus index and spleen index. After modeling the rates’thymus indexes of Sini powders group and Chaishao group were significantly lower than normal group, especially Chaishao group (P<0.05). Compared with model group, besides Chaishaozhi group ,Chaizhigan group, Chaizhi group and Shaozhi group, the rest groups were significant difference. the rates’spleen indexes of modeled rates (P<0.05). Compared with model group, the rates’spleen indexes of control group, Sini powders group and Chaizhigan group increased up significantly.
1.4 NF-κB
The mRNA and activities of NF-κB of all drug groups decrease significantly, especially the Sini powders (P<0.05). The colon mucous membrane NF-κB mRNA of the rates of modle group were obviously higher than normal group’s (P<0.05). Compared with model group, all drug groups were significant difference. In those, Zhigan group was significantly higher than model group (P<0.05).
The colon mucous membrane NF-κB activity of the rates of modle group were obviously higher than normal group’s (P<0.05). Sini powders group was no significant difference with noemal group. Compared with model group, besides Chaigan group and Zhigan group, the rest drug groups were significantly lower (P<0.05). Compared with Sini powders group, the rest drug groups increased significantly (P<0.05).
2 Study of Mechanism on the Sini Powders in Intervening Experimental Ulcerative Colitis
2.1 IL-1β
IL-1βmRNA levels of model group was higher than normal group (P<0.05). Compared with model group, all drug groups were significantly lower (P<0.05). IL-1βprotein activity of model group were obviously higher than normal group (P<0.05). After feeding Chaishaozhi and Chaishao, IL-1βprotein activity of UC rats obviously reduce (P<0.05). But after feeding Sini Powders, there rased significantly (P<0.05).
2.2 TNF-α
TNF-αmRNA and protein levels of model group are higher than normal group (P<0.05). After feeding experimental herbal medicine, TNF-αlevels of UC rats obviously decrease (P<0.05), especially Sini Powders (P<0.05). Compared with Sini powders group, Chaishaozhi group increased significantly (P<0.05), but Chaishao group lowered (P<0.05).
2.3 IL-4
IL-4 mRNA levels of model group are lower than normal group (P<0.05). After feeding Sini Powders and Chaishao, IL-4 levels of UC rats obviously increased (P<0.05), especially Sini Powders (P<0.05). Compared with normal group, IL-4 protein activities of modeled rates were obviously decrease (P<0.05). After feeding experimental herbal medicine, Sini powders group and Chaishao group were obviously higher than model group (P<0.05). And Chaishao group was lowerer than Sini powders group (P<0.05).
2.4 IL-10
IL-10 mRNA levels of model group are lower than normal group (P<0.05). After feeding Sini Powders and Chaishao, IL-10 levels of UC rats obviously increased (P<0.05), especially Sini Powders (P<0.05). Compared with normal group, IL-10 protein activities of modeled rates were obviously decrease (P<0.05). After feeding experimental herbal medicine, Sini powders group and Chaishao group were obviously higher than model group (P<0.05). And Chaishao group was lowerer than Sini powders group (P<0.05).
Conclusion:
The Sini powders can intervene in experimental UC with stimulating the immune organs to excrete the immune cells and inhibit NF-κB activated.
The Sini powders can intervene in experimental UC through adjusting cell factors levels. The mechanism of action chould include:①the Sini powders regulates the balance with inflammatory and anti-inflammatory cytokines through suppressing IL-1βmove and TNF-αsecret.and promoting IL-4 and IL-10 to secret;②the Sini powders can reduce the NF-κB levels of the experimental UC rats, and then regulat and control cytokine network.
材料与方法:
1四逆散不同配伍干预实验性UC的效用研究
将实验大鼠分为14组,采用免疫法造模,以实验大鼠一般状况、结肠组织大体情况、结肠组织病理变化,胸腺指数、脾脏指数和结肠组织NF-κB作为观察与检测指标,用Q-PCR检测核因子-κB(nuclear factor-kappa B,NF-κB)在组织的基因表达,用免疫组化法检测NF-κB的活性。
2四逆散干预实验性UC的机制研究
在“四逆散不同配伍干预实验性UC的效用研究”的基础上,将实验动物分为5组,采用免疫法造模,以实验大鼠结肠组织大体情况、结肠组织病理变化和白细胞介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-4(interleukin-4,IL-4)、白细胞介素-10(interleukin-10,IL-10)作为观察与检测指标,用Q-PCR检测上述细胞因子在组织的基因表达,用ELISA法检测细胞因子活性。
结果:
1四逆散不同配伍干预实验性UC的效用研究
1.1四逆散不同配伍对实验性UC大鼠一般状况的影响
造模第l4天,大鼠多出现食量减少、拱背、聚堆、懒动;第21天,均出现饮食明显减少,稀便、毛发不泽,拱背、聚堆、懒动。各给药组造模大鼠上述症状有不同程度改善。正常组大鼠饮食、大小便、活动正常。给药前后正常组实验大鼠体重平均增长54%,而其他各组实验大鼠体重平均增长范围在32%～38%。
1.2四逆散不同配伍对实验性UC大鼠结肠组织损伤的影响
肉眼观察,模型组大鼠病变结肠肠壁增厚,肠黏膜糜烂,黏膜表面弥漫性充血、水肿,可见出血点和溃疡。各药物治疗组大鼠结肠黏膜表现不同程度充血、水肿,可见轻度糜烂和溃疡。结肠组织损伤程度评分结果显示,造模组大鼠的结肠损伤程度明显高于正常组(P<0.05)。与模型组比较,各药组大鼠的结肠损伤程度显著降低。
光镜下观察,模型组黏膜表面可见溃疡形成,个别深达肌层,炎症反应较重,有充血、糜烂,中性粒细胞浸润,黏膜上皮部分缺失,局部固有层腺体减少,黏膜下层血管增生,黏膜肌层不明显。其余各组均有不同程度的病变。结肠病理组织学评分结果显示,造模组大鼠的结肠病理组织学评分结果明显高于正常组(P<0.05)。与模型组比较,芍甘组和枳甘组无明显差异,其余各组显著降低(P<0.05)。
1.3四逆散不同配伍对实验性UC大鼠胸腺指数与脾脏指数的影响
造模后,模型组和柴芍组大鼠胸腺指数显著低于正常组,以柴芍组降低最为显著(P<0.05),其余各组与正常组无显著性差异;与模型组比较,对照组、四逆散组、柴芍甘组、芍枳甘组、柴芍组、柴甘组、芍甘组和枳甘组大鼠胸腺指数均存在显著差异。造模后大鼠脾脏指数均显著高于正常组(P<0.05);与模型组相比,对照组、四逆散组和柴枳甘组的脾脏指数显著增高(P<0.05)。
1.4四逆散不同配伍对实验性UC大鼠结肠组织NF-κB基因表达及活性的影响
模型组实验大鼠结肠黏膜NF-κB mRNA表达水平明显高于正常组(P<0.05);各药物组实验大鼠结肠黏膜NF-κB mRNA表达水平与模型组比较均存在显著性差异,其中,枳甘组显著高于模型组(P<0.05)。
模型组实验大鼠结肠黏膜NF-κB活性明显高于正常组(P<0.05);四逆散组与正常组比较,无显著差异;除柴甘组和枳甘组外,其余各药物组均显著低于模型组(P<0.05);与四逆散组比较,各药物组显著高于四逆散组(P<0.05)。
2四逆散干预实验性UC的机制研究
2.1四逆散对实验性UC大鼠IL-1β的影响
模型组实验大鼠结肠黏膜IL-1βmRNA表达水平明显高于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著降低(P<0.05)。
模型组和四逆散组实验大鼠血清IL-1β含量明显高于正常组(P<0.05),而柴芍枳组和柴芍组与正常组比较无统计学意义;四逆散组与模型组比较无显著性差异;柴芍枳组和柴芍组显著低于模型组和四逆散组(P<0.05)。
2.2四逆散对实验性UC大鼠TNF-α的影响
模型组实验大鼠结肠黏膜TNF-αm RNA表达水平明显高于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著降低(P<0.05);柴芍枳组明显高于四逆散组(P<0.05),而柴芍组明显低于四逆散组(P<0.05)。与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清TNF-α的含量均明显高于正常组;与模型组比较,四逆散组、柴芍枳组和柴芍组显著降低(P<0.05)。
2.3四逆散对实验性UC大鼠IL-4的影响
模型组实验大鼠结肠黏膜IL-4 mRNA表达水平明显低于正常组(P<0.05);四逆散组和柴芍枳组与正常组比较无显著性差异,而柴芍组则显著高于正常组(P<0.05);与模型组比较,四逆散组、柴芍枳组和柴芍组均显著升高(P<0.05);柴芍枳组和柴芍组均显著高于四逆散组(P<0.05)。
与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清IL-4的含量均明显降低(P<0.05);给药后,柴芍枳组与模型组比较无显著性差异,而四逆散组和柴芍组大鼠明显高于模型组(P<0.05),其中,柴芍组明显低于四逆散组(P<0.05)。
2.4四逆散对实验性UC大鼠IL-10的影响
模型组实验大鼠结肠黏膜IL-10 mRNA表达水平明显低于正常组(P<0.05);四逆散组、柴芍枳组和柴芍组与正常组比较无显著性差异;与模型组比较,四逆散组、柴芍枳组和柴芍组均显著升高(P<0.05)。
与正常组比较,模型组、四逆散组、柴芍枳组和柴芍组实验大鼠血清IL-10的含量均明显降低(P<0.05);给药后,柴芍枳组与模型组比较无显著性差异,而四逆散组和柴芍组大鼠明显高于模型组(P<0.05),柴芍组明显低于四逆散组(P<0.05)。
结论:
四逆散能够干预实验性UC,其作用可能是通过刺激免疫器官分泌免疫细胞,抑制NF-κB的激活来实现的;四逆散对实验性UC作用以全方作用最为理想。
四逆散能够干预实验性UC,其作用机理可能为:①抑制促炎因子IL-1β的移行和TNF-α的分泌,促进抗炎因子IL-4和IL-10的分泌,调节促炎因子和抗炎因子之间的平衡,干预实验性UC;②降低实验性UC大鼠结肠黏膜NF-κB的表达水平,调控UC细胞因子网络。
Purpose:The study of utility and mechanism is the Sini powders and the different compatibilities in intervening experimental ulcerative colitis.
Material and method:
1 Study of Utility on the Sini Powders and the Different Compatibilities in Intervening Experimental Ulcerative Colitis
The experimental animals were divided into 14 groups and modeled with immunization. The states, colon organization and its pathological changes varying, thymus index, spleen index and activity of NF-κB of rats were treated as observation and measurement indicators. NF-κB mRNA was detected by Q-PCR technique. And it’s protein activity was detected by immunohistochemistry.
2 Study of Mechanism on the Sini Powders in Intervening Experimental Ulcerative Colitis Based on the first study, the experimental animals were divided into 5 groups and modeled with immunization. The states, colon organization and its pathological changes varying, IL-1β, TNF-α, IL-4, IL-10 of rats were treated as observation and measurement indicators. And we detected those cell factors mRNA with Q-PCR and activities with ELISA.
Results:
1 Study of Utility on the Sini Powders and the Different Compatibilities in Intervening Experimental Ulcerative Colitis
1.1 The states
Animalpatterns appeared diet reducedg, arch, polyethylene reactor and lazy action at the 14th day, and diet significantly reduced, diarrhea, hair dryed, arch, polyethylene reactor and lazy action at the 21st after modeling. Administrated orally, above symptoms the rats showed improvement with different degree.
The increasing healthy rats' weight was 54%, but the modeling rats’weight increased averagely the range within 32%～38% before and after drug administration.
1.2 Colon Organization and its Pathological Changes
With visualinspection, we found the intestinal wall thicken, mucous membrane erosion, suiface of mucous membrane diffuse congestion and edema of the rates colons of model group. And blutpunkte and ulcer cound be observed. But all treatment groups were improved inordinately. The experimental result showed the model group was significant difference with normal group (P<0.05). Compared with model group, the degrees of colonic injury of all drug groups were significantly lower (P<0.05).
Under light microscope, we observed there were ulceration, neutrophilicgranulocyte infiltration, congestion, erosion, epithelium deletion, lamina propria gland lessen, vessel hyperplasia of the rates colons of model group. The experimental result showed the model group was significant difference with normal group (P<0.05).Compared with model group, besides Chaishao group and Zhigan group, the rest groups were all significantly lower.
1.3 Thymus Index and Spleen Index
The different compatibilities can improve significantly thymus index and spleen index. After modeling the rates’thymus indexes of Sini powders group and Chaishao group were significantly lower than normal group, especially Chaishao group (P<0.05). Compared with model group, besides Chaishaozhi group ,Chaizhigan group, Chaizhi group and Shaozhi group, the rest groups were significant difference. the rates’spleen indexes of modeled rates (P<0.05). Compared with model group, the rates’spleen indexes of control group, Sini powders group and Chaizhigan group increased up significantly.
1.4 NF-κB
The mRNA and activities of NF-κB of all drug groups decrease significantly, especially the Sini powders (P<0.05). The colon mucous membrane NF-κB mRNA of the rates of modle group were obviously higher than normal group’s (P<0.05). Compared with model group, all drug groups were significant difference. In those, Zhigan group was significantly higher than model group (P<0.05).
The colon mucous membrane NF-κB activity of the rates of modle group were obviously higher than normal group’s (P<0.05). Sini powders group was no significant difference with noemal group. Compared with model group, besides Chaigan group and Zhigan group, the rest drug groups were significantly lower (P<0.05). Compared with Sini powders group, the rest drug groups increased significantly (P<0.05).
2 Study of Mechanism on the Sini Powders in Intervening Experimental Ulcerative Colitis
2.1 IL-1β
IL-1βmRNA levels of model group was higher than normal group (P<0.05). Compared with model group, all drug groups were significantly lower (P<0.05). IL-1βprotein activity of model group were obviously higher than normal group (P<0.05). After feeding Chaishaozhi and Chaishao, IL-1βprotein activity of UC rats obviously reduce (P<0.05). But after feeding Sini Powders, there rased significantly (P<0.05).
2.2 TNF-α
TNF-αmRNA and protein levels of model group are higher than normal group (P<0.05). After feeding experimental herbal medicine, TNF-αlevels of UC rats obviously decrease (P<0.05), especially Sini Powders (P<0.05). Compared with Sini powders group, Chaishaozhi group increased significantly (P<0.05), but Chaishao group lowered (P<0.05).
2.3 IL-4
IL-4 mRNA levels of model group are lower than normal group (P<0.05). After feeding Sini Powders and Chaishao, IL-4 levels of UC rats obviously increased (P<0.05), especially Sini Powders (P<0.05). Compared with normal group, IL-4 protein activities of modeled rates were obviously decrease (P<0.05). After feeding experimental herbal medicine, Sini powders group and Chaishao group were obviously higher than model group (P<0.05). And Chaishao group was lowerer than Sini powders group (P<0.05).
2.4 IL-10
IL-10 mRNA levels of model group are lower than normal group (P<0.05). After feeding Sini Powders and Chaishao, IL-10 levels of UC rats obviously increased (P<0.05), especially Sini Powders (P<0.05). Compared with normal group, IL-10 protein activities of modeled rates were obviously decrease (P<0.05). After feeding experimental herbal medicine, Sini powders group and Chaishao group were obviously higher than model group (P<0.05). And Chaishao group was lowerer than Sini powders group (P<0.05).
Conclusion:
The Sini powders can intervene in experimental UC with stimulating the immune organs to excrete the immune cells and inhibit NF-κB activated.
The Sini powders can intervene in experimental UC through adjusting cell factors levels. The mechanism of action chould include:①the Sini powders regulates the balance with inflammatory and anti-inflammatory cytokines through suppressing IL-1βmove and TNF-αsecret.and promoting IL-4 and IL-10 to secret;②the Sini powders can reduce the NF-κB levels of the experimental UC rats, and then regulat and control cytokine network.
引文
[1]朱筱莲.四逆散加味治疗消化性溃疡98例[J].广西中医药,2001,24(5):40.
[2]邵丽黎.血竭四逆散治疗消化性溃疡50例[J].陕西中医,2003,24(1):17-18.
[3]刘德昭.四逆散加味治疗消化性溃疡40例[J].中国现代医生,2009,47(23):75-75,111.
[4]祁长虹,原培稼,郭爱则.四逆散加味治疗胆汁反流性胃炎30例临床观察[J].北京中医药大学学报,1997,20(3):68.
[5]杜曦.四逆散加味治疗慢性胃炎67例.浙江中西医结合杂志[J].2003,13(5):35-36.
[6]王华.慢性浅表性胃炎中医辨治临床探讨[J].中国现代药物应用,2010,4(1):117-118.
[7]姜周明.四逆散治疗胃肠运动障碍型功能性消化不良40例[J].中国中西医结合脾胃杂志,2000,8(4):251.
[8]薛红记.四逆散合六君子汤治疗功能性消化不良52例[J].中国中医药科技,2001,8(1):58.
[9]姜传田,马庭鑫.浅谈四逆散加减治疗功能性消化不良[J].中国中医药咨讯,2010,2(2):229.
[10]周向阳,王世勋,王荣林.四逆散为主辨证治疗肠易激综合征120例[J].国医论坛,1999,14(1):7.
[11]方杰.百合汤加四逆散治疗便秘型肠易激综合征36例[J].中国乡村医药,2009,16(5):53.
[12]杨洁.四君子汤配合四逆散治疗肠易激综合征临床研究[J].湖北中医杂志,2009,31(7):16-17.
[13]肖成.四逆散加味治疗慢性溃疡性结肠炎[J].内蒙古中医药,1998,17(1):26-27.
[14]张炜.四君子汤合四逆散加味治疗溃疡性结肠炎[J].成都中医药大学学报,2002,25(2):8-10.
[15]王如茂,胡开生.痛泻要方合四逆散加味治疗肝郁脾虚型溃疡性结肠炎58例[J].中医杂志,2008,24(5):438-439.
[16]扬大仁.四逆散加减治疗溃疡性结肠炎的体会[J].内蒙古中医药,2009,28(8):61.
[17]陶琳,肖旸,李帷,等.四逆散合左金丸联合雷贝拉唑治疗胃食管反流病36例[J].北京中医药,2009,28(10):785-787.
[18]刁喜凤,迟竹云.四逆散加味治疗肝脾曲结肠综合征28例[J].河南中医药学刊,1999,14(4):44-45.
[19]冯桂梅,张玉莲.四逆散加味治疗胃粘膜异型增生20例[J].长春中医学院学报,1998,14(2):15.
[20]刘海清,历淑芬,张俊杰,等.四逆散治便秘举隅[J].云南中医中药杂志,2009,30(7):42-43.
[21]龚时贤.茵惹四逆散治疗乙型肝炎42例[J].陕西中医,2001,22(7):400-401.
[22]刘星.加味四逆散抗拉米夫定停药后慢性乙型肝炎复发12例[J].中国中西医结合杂志,2002,22(8):593.
[23]王南.四逆散加减治疗慢性肝炎顽固性呃逆29例[J].实用中医内科杂志,2003,17(1):5.
[24]张天录,刘改莲,吴斌.加味四逆散治疗脂肪肝17例疗效观察[J].内蒙古中医药,1996,15(2):7.
[25]毛志远,王驰.四逆散合异功散治疗非酒精性脂肪肝3O例[J].浙江中医杂志,2009,44(6):429.
[26]刘亚军,王佳,王春生.加味四逆散治疗2型糖尿病脂肪肝肝损害临床观察[J].北京中医药,2009,28(7):530-531.
[27]王爱坚.四逆散为主治疗肝硬化腹水32例[J].山西中医,1999,15(2):34.
[28]孙守才,刘光炜.加味四逆散治疗慢性乙型肝炎肝纤维化的初步研究[J].陕西中医学院学报,2001,24(1):46-47.
[29]冯根凤,金朝辉,罗春香.四逆散加减治疗肝硬化肠源性内毒素血症体会[J].中国中医药信息杂志,2009,16(11):78.
[30]狄群英.四逆散加味治疗慢性胆囊炎54例[J].云南中医药杂志,1999,20,(1):23-24.
[31]卢艳晨.威金四逆散治疗慢性胆系疾患50例[J].陕西中医,2002,23(7):591.
[32]陈永敏.四逆散加味治疗慢性胆囊炎110例[J].中国中医药现代远程教育,2009,7(9):127.
[33]王如高,陈二军.补母实子法治疗难治性早搏32例[J].山西中医,1997, 13(3):55.
[34]杨洪军,孟繁蕴,孔立.四逆散加减治疗心脏神经官能症40例[J].浙江中医杂志,1998,33(4):155.
[35]雷健,丁红涛,吴艳霞.疏泄肝胆治疗冠心病心绞痛临床疗效分析[J].浙江中西医结合杂志,1998,8(2):93-94.
[36]杨永勤,李凤.四逆散加味治疗末梢神经炎25例[J].实用中医药杂志,2002,l8(11):28.
[37]薛汉荣,冷天文.黄连温胆汤合四逆散治疗失眠30例临床观察[J].江西中医药,2004,35(3):35.
[38]张帅.四逆散加味治疗2型糖尿病周围神经病变51例[J].中国中医药信息杂志,2008,15(9):56.
[39]张涛.四逆散加味治疗慢性血管紧张性头痛56例[J].中国医药指南,2009,7(10):77-78.
[40]杨晓晖.吕仁和教授运用四逆散治疗肾系疾病撮要[J].辽宁中医杂志,1996,23(9):387.
[41]杨红萍.四逆散加味治疗甲状腺机能亢进21例[J].实用中医药杂志,1996,3(4):14.
[42]郝小梅,刘梅.加味四逆散治疗痒咳42例[J].江西中医药,2009,40(7):18-19
[43]郑星宇,杜思哲,任林,等.四逆散合小青龙汤治疗哮喘急性发作期体会[J].浙江中医杂志,2010,45(2):111-112.
[44]巫嘉琴.四逆散合金铃子散治疗乳腺增生症88例[J].广西中医药,1998,21(6):29.
[45]白念兰,赵临浩.地肤子合四逆散加减治疗乳腺增生60例[J].中国民间疗法,2003,11(1):41.
[46]金锡蓉,杨胜强.四逆散加减治疗乳腺增生症55例[J].中国中医急症,2009,(8):1344.
[47]叶春娟.四逆散加味治疗盆腔炎48例[J].吉林中医药,2003,23(4):26.
[48]易蕾,黄梅,农夏欣,等.四逆散加味治疗慢性盆腔炎75例[J].江西中医药,2009,40(9):40-42.
[49]李艳萍,国亚利.四逆散合失笑散治疗原发性痛经80例[J].河北中医,1991,19(3):16-17.
[50]王晓萍,吴建红.金铃四逆散治疗痛经的临床观察与机理探讨[J].江西中医药,1998,29(2):18.
[51]姬淑琴.四逆散在妇科临床中的应用[J].山西中医,2000,16(2):50-51.
[52]贾思明,贾采云.益母石英四逆散加味治原发不孕[J].中国乡村医生,1998,14(11):39.
[53]张晓春.归肾丸合四逆散治疗排卵障碍性不孕症59例[J].山东中医杂志,2002,21(7):404-405.
[54]庞玉琴.四逆散加味治疗不孕症60例[J].陕西中医,2003,24(5):416-417.
[55]苏良溪.四逆散加味治疗前列腺肥大30例[J].福建医药杂志,1995, 17(6):200
[56]毛发勤.四逆散加味治疗阳痿54例[J].中国民间疗法,1999,7(6):28.
[57]陈柏莲.四逆散加味治疗不射精性不育症36例临床观察[J].北京中医,2000,19(1):40.
[58]蒋政余.四逆散加味治疗慢性附睾炎32例[J].湖南中医杂志,2001,17(2):29.
[59]庞宏永,杨曦,刘学伟.四逆散加味治疗精液不液化症36例[J].河北中医,2002,24(1):45.
[60]张伟宏,王君.四逆散加味治小儿厌食症64例[J].国医论坛,1996,11(5):16.
[61]詹雪梅,吴长明.四逆散加味治疗小儿腹痛58例[J].浙江中西医结合杂志,2000,10(5):62.
[62]王树红.四逆散加味治疗小儿发热54例临床观察[J].光明中医,2009,24(10):1909.
[63]吴辉,刘利萍.加味四逆散治疗小儿食积130例[J].福建中医药,2009,40(4):29-30.
[64]彭成,张磊,张利,等.四逆散治疗功能性消化不良的实验研究[J].成都中医药大学学报,1999,22(1):40-42.
[65]牛路芳,邱明义,石拓,等.四逆散治疗功能性消化不良的神经元及神经递质实验研究[J].时珍国医国药,2005,16(12):60-61.
[66]邓青秀,彭延娟,彭成,等.四逆散对肝郁证模型大鼠胃肠组织细胞形态及胃肠激素的影响[J].中国实验方剂学杂志,2007,13(6):33-36.
[67]王惠洁,杨蓉,林棋.四逆散和阿托品对离体兔肠平滑肌松弛作用的比较研究[J].山西中医学院学报,2006,7(5):20-21.
[68]李冀,毕辉,孙宇峰.四逆散抗实验性胃溃疡的药效学及作用机理研究[J].中华中医药学刊,2007,25(7):1317-1319.
[69]赵莹,王玉玫,丁淑霞,等.四逆散对大鼠胆汁流量的影响[J].中医药信息,2000,7(4):65-66.
[70]王东强,张国骏,史丽萍.四逆散对肝损害细胞bax基因表达的影响[J].天津中医药,2005,20(2):155-157.
[71]蒋洁云,徐强.四逆散及其各组成中药对实验性肝损伤的影响[J].中国天然药物,2004,2(1):46-50.
[72]金艳,王庆国,石任兵,等.四逆散活性成分对慢性应激诱导的抑郁症模型大鼠大脑皮层与海马5-HT(1A)受体mRNA表达的影响[J].北京中医药大学学报,2004,27(4):34-36.
[73]畅洪昇,王庆国,石任兵,等.四逆散活性成分对抑郁症大鼠慢性应激模型行为学及脑内单胺类神经递质的影响[J].北京中医药大学学报,2003,26(5):42-45.
[74]畅洪昇,梁吉春,孙建宁,等.四逆散有效部位对小鼠行为绝望和药物抑郁模型的作用[J].北京中医药大学学报,2006,29(7):451-453.
[75]畅洪昇,孙建宁,石任兵,等.四逆散有效部位对嗅球损毁大鼠海马细胞发生及CREB基因拷贝数量的影响[J].中国药学杂志,2006,41(14):1069-1071,1096.
[76]童瑶,邹军,倪力强,等.4种中药复方对大鼠实验性急性应激行为及下丘脑-垂体-肾上腺轴的影响[J].中国中药杂志,2005,30(23):1863-1866.
[77]童瑶,邹军,刘平,等.四种中药复方对急性心理应激大鼠IL-1β和IL-2的影响[J].上海中医药大学学报,2005,19(2):32-34.
[78]龚传美,管喜文,张军,等.四逆散对血粘度和甲襞微循环的作用[J].临床军医杂志,1991,19(4)9-11.
[79]龚传美,魏爱红,管喜文,等.四逆散对人、小白鼠微循环的影响[J].中药药理与临床,1991,7(2):6-7.
[80]刘珊珊,李廷利,朱维莉.四逆散对失眠大鼠睡眠时相的影响[J].中国医药导报,2008,5(15):19,36.
[81]李廷利,朱维莉,齐凤琴,等.四逆散催眠作用的实验研究[J].中医药信息,2004,21(1):59-60.
[82]李庆岚,齐云华,龚传美,等.四逆散抗VSV病毒和诱生干扰素的实验研究[J].中药药理与临床,1992,8(6):13-15.
[83]管喜文,龚传美,郑全清.四逆散抗疲劳作用实验观察[J].临床军医杂志,1992,20(3):9-10,8.
[84]李维,孔烈,于爽,等.四逆散对运动性疲劳大鼠海马突触素的调节作用[J].中国康复理论与实践,2009,15(8):739-741.
[85]龚传美,管希文,兰克信.四逆散的抗休克作用研究[J].中药药理与临床.1989,5(2):1-4.
[86]李岩,陈苏宁,李宇权,等.芍药甘草汤、四逆散对胃排空及小肠推进功能影响的拆方研究[J].中华消化杂志,1996,16(1)18-21.
[87]李强.四逆散对大鼠胃酸分泌、胃蛋白酶活性及预防应激性溃疡的基础研究[D].中国医科大学,硕士毕业论文,2002.
[88]郭际.四逆散有效成分提取和成分分析研究[D].成都中医药大学,硕士毕业论文,2002.
[89]韩向东,陈少丽,陈德兴,等.柴胡、白芍抗CCl4致实验性肝损伤的配伍规律研究[J].中国中医基础医学杂志,2005,11(8):593-594,598.
[90]李越峰,黄玉新,李廷利,等.四逆散拆方过程中成分变化的分析研究[J].中成药,2009,31(8):1308-1310.
[91]李军,石任兵,刘斌,等.四逆散不同配伍对甘草素和异甘草素煎出量的影响[J].北京中医药大学学报,2006,29(12):847-850.
[92]李军,石任兵,刘斌,等.四逆散不同配伍对柴胡皂苷a、b2及柴胡总皂苷煎出量的影响[J].北京中医药大学学报,2007,30(2):115-120.
[93]李军,姜华,石任兵,等.四逆散不同配伍对柴胡皂苷b1,h提取量的影响[J].中国中药杂志,2008,33(15):1912-1914.
[94]中华医学会消化病学分会.对炎症性肠病诊断治疗规范的建议(2000年)[J].现代实用医学,2003,15(10):656-659.
[95]Baumgart DC,Carding SR.Inflammatory bowel disease:cause and immunobiology [J]. Lancet,2007,369(9573):1627-1640.
[96]葛柳青,夏冰.炎症性肠病的基础研究与临床应用[J].中国处方药,2010,95(2):35-37.
[97]Bamias G,Nyce MR,De La Rue SA,eta1.New conception in the pathophysiology of inflammatory bowel disease[J].Ann Intern Med,2005,143(12):895-904.
[98]Ardizzone S, Porro GB. Comparative tolerability of therapies for ulcerative colitis[J]. Drug Saf,2002,25(8):561.
[99]吴国豪.肠道屏障功能[J].肠外与肠内营养,2004,11(1):44-47.
[100]赵树铭,康格非.前列腺素合酶-2的研究进展[J].国外医学临床生物化学与检验学分册,1998,19(4):103-106.
[101]毕涉,高骥授.炎症与抗炎症药物[M].北京:人民卫生出版社,1994:9,13-27,20-26.
[102]丁连安.肠屏障功能障碍[J].肠外与肠内营养,2005,12(1):55-58.
[103]田海河,董建华,田德录,等.中药治疗溃疡性结肠炎的临床及实验研究[J].北京中医药大学学报,1995,18(5):47-49.
[104]朱湘生,周泽泉,冯利君,等.消化系统疾病辨证与TXA2,PGI2的临床意义[J].中国中西医结合脾胃杂志,1998,6(3):172-173.
[105]张连峰,田曙光,王国新.溃疡性结肠炎患者血小板功能状态的研究[J].中国实用内科杂志,2000,20(2):98-99.
[106]方维丽.环氧合酶2和前列腺素在溃疡性结肠炎中的作用[J].中华内科杂志,2003,42(9):55.
[107]吴升华.脂氧素与白三烯研究进展[J].生理科学进展,1996,27(1):79-81.
[108]王晓兰.溃疡性结肠炎动物模型及研究进展[J].洛阳医专学报,2002,20(1):88-90.
[109]董梅,周喆，朱传樽.小儿炎症性肠病的研究进展[J].国外医学儿科学分册,1999,26(3):113-116.
[110]Kaufmann JA , Bickford PC , Taglialatela G.Free radical-dependent changes in constitutive Nuclear factor kappa B in the aged hippocampus[J].Neuroreport,2002,13(15):1917-1928.
[111]Nystrom T.The free-radical hypothesis of aging goes prok aryotic[J]. Cellular and molecular life sciences,2003,60(7):1333-1341.
[112]朱炳喜,吕愈敏.氧自由基在溃疡性结肠炎发病机制中的研究[J].中华消化内镜杂志,1997,14(2):40-41.
[113]马春曦,李志晋,詹丽英,等.溃疡性结肠炎大鼠肠组织中MDA、SOD、损伤指数的动态变化及其相关性研究[J].江西医学院学报,2005,45(3):4-6.
[114]张海燕,黄穗平,黄绍刚,等.清热祛湿法对实验性溃疡性结肠炎大鼠黏膜损伤的影响[J].时珍国医国药, 2010,21(2):354-356.
[115]吕永慧.溃疡性结肠炎的研究近况[J].中国中西医结合脾胃杂志,1996,4(2):116-119.
[116]张海燕,黄穗平,黄绍刚,等.清热祛湿法对实验性溃疡性结肠炎大鼠黏膜损伤的影响[J].时珍国医国药,2010年,21(2):354-356.
[117]黄俊,罗和生,李颖.大鼠实验性溃疡性结肠炎中NO、MDA、SOD的变化[J].武汉大学学报(医学版),2002,2(2):146-148.
[118]陈吉.一氧化氮与溃疡性结肠炎[J].世界华人消化杂志,2000,23(8):324-325.
[119]陈吉,吕愈敏,叶嗣懋,等.活动期溃疡性结肠炎与一氧化氮关系的临床研究[J].中华消化杂志,1998,18(5):295-297.
[120]陈垦,汤斌,祝斌,等.溃疡性结肠炎患者血清一氧化氮检测及意义[J].中国医师杂志,2002,4(10):1073-1074.
[121]崔淑华.解毒化瘀扶正中药对溃疡性结肠炎大鼠体内三种炎症介质的影响[D].河北医科大学,硕士毕业论文,2005.
[122]Rachmilewitz D,Eliakim R,Simon P,et al.Cytokines and platelet activating factor in human inflamed colonic mucosa[J].Agents Actions,1992,36(9):C32-36.
[123]许丽莉,王吉耀.活动期溃疡性结肠炎患者体内血小板激活状态的评价[J].中化消化杂志,2002,22(5):285-287.
[124]施昕,魏龙富,俞翁非,等.溃疡性结肠炎患者凝血功能改变[J].中华消化杂志,2002,22(4):6.
[125]李虹义,吴开春.血小板活化因子溃疡性结肠炎患者结肠粘膜的释放及其对结肠分泌的影响[J].医学信息,1996,9(12):30-31.
[126]Hawrelak JA,Myers SP.The causes of intestinal dysbiosis:a review[J].Altem Med Rev,2004,9(2):180-197.
[127]Kanauchi O,Mitsuyama K,Araki Y,et a1.Modification of intestinal flora in the treatment of inflammatory bowel disease[J].Curr Pharm Des,2003,9(4):333-346.
[128]刘力,张欢.肠道菌群失调与溃疡性结肠炎[J].现代中医药,2010,30(2):45-47
[129]李润美,韩英.肠道菌丛与炎症性肠病[J].现代消化及介入诊疗,2006,11(1):48-50.
[130]熊德鑫.现代微生态学[M].北京:中国科学技术出版社,2000,252-255.
[131]崔熠.溃疡性结肠炎患者结肠粘膜嗜酸性粒细胞和粪便菌群的研究[D].中南大学,硕士毕业论文,2009.
[132]Lim WC,Hanauer SB.Controversies with aminosalieylates in inflammatory bowel disease[J].Rev Gastroenterol Disord,2004,4(3):104-107.
[133]Laroux Fs,Pavliek KP,Wolf RE,et al.Dysregulation of intestinal mucosa immunity:implications in inflammatory bowel disease[J].News Physiol Sci,2001,16(6):272-277.
[134]夏冰.炎症性肠病的病因与发病机制[J].世界华人消化杂志,2001,9(3):245-250.
[135]Dasgupta A,Mandal A,Das M.Circulating immunoglobulin G1 antibody in patient with ulcerative colitis against the colonic epithelial protein detected by a novel monoelonal antibody[J].Gut,1994,35(12):1712-1717.
[136]Bach MA.The use of monoclonal anti-Tcell antibodies to study T cell inbalances in human disease[J].Clin Exp Im-munol,1981,45:449-456.
[137]王巧民,翟志敏.溃疡性结肠炎T淋巴细胞亚群检测及其意义[J].中华消化杂志,2002,22(6):366-367.
[138]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者T淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4):220-222.
[139]邓志波.溃疡性结肠炎外周血T淋巴细胞亚群的研究[J].河北医学,2006,10(8):675.
[140]Bhan AK,Mizoguchi E,SmithR N,et al.Colitis in transgenic and knockout animals as models of human inflammatory bowel disease[J].Immunol Rev,1999,169(1):195-207.
[141]Yoshizaki N,Sakamaki S,Takayanaki N,et al.Increased population of Th2 like cells with a phenotype of CD45RO+CD62L+ in patients with ulcerative colitis[J]. Gastroenterology,1998,suppl(4):G458.
[142]Lim WC,Hanauer SB.Controversies with aminosalicylates in inflammatory bowel disease[J].Rev Gastroenterol Disord,2004,4(3):104-107.
[143]De Jager PL,Franchimont D,Waliszewska A,et al.The role of the Toll receptor pathway insusceptibility to inflammatory bowel diseases[J].Genes Immun,2007,8(5):387-397.
[144]Abreu,Maria T.Immunologic regulation of toll-like receptors in gut epithelium[J]. Gastroenterol,2003,19(6):559-564.
[145]Sen R,Baltimore D.Indueibility of the immunoglobulin enhancer-binding Protein NF- kappa B by a posttranslatinonal mechanism[J].Cell,1986,47(6):921-928.
[146]Abreu MT,Vora P,Fature E,et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopoly saccharide[J].J Immunol,2001,167(3):1609-1617.
[147]Liu Y,Wang Y,Yamankuchi M,et al. Upregulation of Toll-like receptor gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is invoived in NF-κB activation[J]. Infection Immun,2001,69(5):2788-2796.
[148]田海河,李庆荣.中医药治疗溃疡性结肠炎思路方法的分析[J].中国中医药信息杂志,1995,2(9):23-24.
[149]陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4):11-12.
[150]王蕊.中医综合疗法治疗溃疡性结肠炎30例[J].湖北中医杂志,2005,27(12):23-24.
[151]王新月,田德禄.溃疡性结肠炎病因病理特点与中医辨治思路对策[J].北京中医药大学学报,2007,30(8):554-555.
[152]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-252.
[153]王向红,李佃贵,张金丽,等.“以方测证"验证化浊解毒对溃疡性结肠炎大鼠血清TNF-α、IL-1β的影响[J].现代中西医结合杂志,2010,19(9):1056-1057,1135.
[154]刘成高,饶群阳.陈光伟治疗慢性溃疡性结肠炎经验[J].实用中医药杂志,2004,20(2):88.
[155]徐王番,李守朝.培土抑木法在防治结肠炎中的应用[J].陕西中医,2006,27(12):1548-1549.
[156]王希利,彭艳红,孙明袜,等.溃疡性结肠炎以肺脾痰瘀论治研究[J].辽宁中医杂志,2007,34(6):747-748.
[157]田旭,白光.溃疡性结肠炎中医病因病机探要[J].实用中医内科杂志,2009,23(3):44-45.
[158]徐叔云,卞如濂,陈修.药理实验方法学[M].3版,北京:人民卫生出版社,2002:1335.
[159]李杨.溃疡性结肠炎动物模型的建立方法[J].中药新药与临床药理,1999,10(2):56-58.
[160]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通报,1998,14(4):86-88.
[161]朱峰,钱家鸣,潘国宗.细胞免疫反应性炎症性肠病动物模型的建立[J].中国医学科学院学报,1998,20(4):271-278.
[162]Tjandra K,Le T,Swain MG. Experimental colitis attenuates development of toxin- induced cholangitis in rats[J]. Digestive diseases and sciences,2002,47(6):1216-1223.
[163]Livard KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and 2-△△CT method[J]. Methods,2001,25(4):402-408.
[164]Wang T,Wang Y,Wu MC,et a1.Activating mechanism of transcriptor NF-Kappa B regulated by hepatitis B virus X protein hepatocellular carcinoma[J].World J Gastroenterol,2004,l0(3):356.
[165]国家药典委员会.中华人民共和国中药部颁标准(2010年版一部)[M].北京:中国医药科技出版社,2010:147,96.
[166]黄煌.张仲景50味药证[M].北京:人民卫生出版社,2008:85.
[167]YenMH,Lin CC,Yen CM.The immunomodulatory effectof saikosaponin derivatives and the root extract of Bupleurum kaoi in mice[J]. PhytotherRes,1995,9(4):351-358.
[168]梁云,崔若兰.柴胡皂甙及其同系物抗炎和免疫功能的研究进展[J].中国中西医结合杂志,1998,18(7):446-447.
[169]Kato M,Pu MY,Isobe KI,et al. Characterization of the immuno regulatory action of Saikosaponind[J].Cell Immunol,1994,159(1):15-17.
[170]王本祥.现代中药药理与临床[M].天津:天津科技翻译出版公司,2004:1242.
[171]王兴旺,陈敏珠,徐叔云.白芍总苷对T淋巴细胞亚群的作用[J].中国药理学通报,1992,8(5):340-344.
[172]李俊,梁君山,周爱武,等.白芍总甙对B淋巴细胞增殖和白介素-1生成的调节作用[J].中国药理学与毒理学杂志,1994,8(1):53-54.
[173]江苏新医学院.中药大辞典(下册)[M].上海:上海人民出版社,1977:1509-1510.
[174]Currier NL,Lejtenyi D,Miller SC.Effect over time of in-vivo administration of the polysaccharide arabinogalactan on immune and hemopoietic cell lineages in murine spleen and bone marrow[J].Phytomedicine,2003,10(2-3):145-153.
[175]李发胜,赵珏,池晓峰,等.甘草多糖对小鼠免疫调节作用的影响[J].中国中医药信息杂志,2009,16(6):35-36.
[176]Sung TS,La JH,Kim TW,et a1.Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat[J].J Veteri Sci,2006,7(2):143-150.
[177]Mc Alindon ME,Hawkey CJ,Mahida YR. Expression of interleukin 1βand interleukin 1βconverting enzyme by intestinal macrophages in health and inflammatory bowel disease[J].Gut,1998,42(2):214-219.
[178]马贵同,詹剑烈.中医中药治疗溃疡性结肠炎临床及实验研究[J].中医杂志,1985,26(7):33-35.
[179]Onderdonk AB,Steves RM,Cisneros RL,et a1.Adoptive transfer of immune enhancemcnt of experimental ulcerative colitis[J].Infect Immun,1984,46(1):64-67.
[180]邱绮玉,熊伍军,杨光,等.结肠宁对实验性溃疡性结肠炎的疗效观察[J].中国中西医结合脾胃杂志,1999,7(l):54-55.
[181]Jurius AR,Khoury NN,Reimund JM.Animal models of inflammatory bowel disease [J].J Pharmacol Toxicolog Methods,2004,50(2):81-92.
[182]Suzuki R,Kohno H,Sugie S,et a1.Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate induced colon carcinogenesis in mice[J].Carcinogenesis,2006,27(1):162-169.
[183]Rachimlewitz D,Stamler JS,Farmli F,et al.Peroxynitrite-induce rat colitis A new model of colonic inflammation[J].Gastroenterology,1993,105(6):1681-1688.
[184]黄永年,张元德,刑玉馥.大鼠溃疡性结肠炎模型的建立与观察[J].中华病理学杂志,1995,24(6):392.
[185]夏冰,黄梅芳,付苓.细胞免疫反应性溃疡性结肠炎模型[J].中华实验外科杂志,1992,9(3):130-131.
[186]任晋斌,许卫红,马文运,等.柳氮磺吡啶栓治疗实验性结肠炎的药效学研究[J].中国医药工业杂志,1993,24(9):408-410.
[187]Jewell DP.Ulcerative colitis,advances in medical treatment[M].Blackwell Scientiric Publ,1995,153.
[188]Morris GP,BecF PL,Herridge MS,et al.Hapten induced model of chronic inflanation and ulceration in the rat colon[J].Gastroenterology,1989,96(3):795-803.
[189]Podolsky DK.IBD:the dialectic of clinical advances and challenges[J].Dig Liver Dis,2005,37(1):1-2.
[190]Dohi T,Fujihashi K,Kiyono H,et al.Mice deficient in Th1-type and Th2-type cytokines develop distinct forms of hapten-induced colitis[J]. Gastroenterology,2000,119(3):724-733.
[191]Schreiber S,Heining T,Panzer U,et al.Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease[J]. Gastroenterology,1995,108(1):21-33.
[192]周天羽,张扬,王俊江,等.免疫复合法建立大鼠溃疡性结肠炎模型的研究[J].中医药学报,2005,33(6):23-24.
[193]江学良,权启镇,王东,等.复合法建立大鼠溃疡性结肠炎模型[J].青海医学院学报,1999,20(4):1-3.
[194]Rennick D,Davidson N,Berg D.Interleukin-10geneknock-outmice:a model of chronic inflammation[J].Clinical ImmunOlogy and Immunopathology,1995,76(3):S174-178.
[195]Ostanin,Pavlivk KP,Bharwani S,et a1.T cell induced inflammation of the small and large intestine in immunodeficient mice [J].Am J Physiol Gastrointest Liver Physiol,2006,290(1):G109-l19.
[196]Dieleman LA,Goerres MS,Arends A,et a1.Lactobacillus GG prevents recurrence ofcolitis in HLA-B27 transgenic rats after antibiotic treatment[J].GUT,2003,52(3):370-376.
[197]Aranda R,Sydora BC,McAllister PL,et a1.Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+,CD45RB high T cells to SCID recipients[J].J Immunol,1997,158(7):3464-3473.
[198]Madara JL,Podolsky DK,King NW,eta1.Characterization of spontaneous colitis in cotton-top tamarins ( saquinus oedipus ) and its response to sulfasalazine[J]. Gastroenterology,1985,88(1):13-19.
[199]Rogler G,Andus T. Cytokines in inflammatory bowel disease[J].World J Sung,1998,22(4):382-389.
[200]Manida YR,Wu K,Jewell DP. Enhanced production of Intericukin-1βin mononuclear cells isolated from mucosa with active ulcerative colitis and Crohn's disease[J].Gut,1989,30(6):835-838.
[201]Isaacs KL,Sartor RB,Haskill S.Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification[J]. Gastroenterology,1992,103(5):1587-1595.
[202]Ashwood P,Harvey R,Verjee T. Functional interactions between mucosal IL-l,IL-lraand TGF-beta 1 in ulcerative colitis[J].Inflamm Res,2004,53(2):53.
[203]Gan H,Ouvan Q,Jia D,et al. Activation of nuclear factor-kappaB and its relationship with cytokine gene expression in colonic mucosa of ulcerative colitis patients[J]. Zhonghua Nei Ke Za Zhi,2002,41(4):252-255.
[204]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的试验性研究[J].现代预防医学,2005,32(7):735-736.
[205]Sivakamar PV,Westric GM,Kanaly S,et al. Interleukin 18 is a primary mediator of the inflammatory associated with dextral sulphate sodium induced colitis-blocking interleukin 18 attenuates intestinal damage[J].Gut,2002,50(6):812,20.
[206]张可,邓长生,朱尤庆,等.溃疡性结肠炎组织中NF-κB,cox-2和iNOS表达的意义[J].世界华人消化杂志,2002,10(5):575-578.
[207]J F Mouser,Pham D,J S Hyams. Infliximab:a novel chimeric monoclonal antibody for the treatment of Crohn’Disease[J].Clinical Therapeutics,1999,21(6):932-942.
[208]祝斌,李巧勤,陈垦,等.溃疡性结肠炎患者周围血中性粒细胞凋亡与细胞因子水平的关系[J].临床消化病杂志,2003,15(6):254-256.
[209]Bonizzi G,Karin M. The two NF-kB activation pathways and their role in innate and adaptive immunity[J].Trends Immuno1,2004,25(6):280-288.
[210]朱萱萱,沈洪,施荣山,等.肠安胶囊治疗大鼠免疫性溃疡性结肠炎的实验研究[J].中国中医药科技,2002,9(1):19-21.
[211]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报(医学科学版),2001,28(4):330-333,375.
[212]Mosmann TR,Moore KW. The Role of IL-10 in Cross Regulation of Th1 and Th2 Responses[J].Immunology Today,1991,12(3):A49-53.
[213]Schreiber S,Heinig T,Thiele HG,et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease[J].Gastroenterology,1995,108(5):1434-1444.
[214]Cui HH,Chen CL,Wang JD,et al. Effect sofprobiotic on intestinal mucosa of patients with ulcerative colitis[J].World J Gastroentero,J 2004,10(10):1521-1525.
[215]许昌泰,郭学刚.溃疡性结肠炎与免疫因素[J].世界感染杂志,2004,4(6):524-526.
[216]Gustot T,Lemmers A,Louis E,et al. Profile of soluble cytokine receptors in Crohn’s disease[J].Gut,2005,54(4):488-495.
[217]Saniabadi AR,Hanai H,Suzuki Y,et al. Adacolumn for selective leukocyte-pheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy [J].J Clin Apher,2005,20(3):171-184.
[218]Sen R,Baltimore D. Indueibility of the immunoglobulin enhancer-binding Protein NF-Kappa B by a posttranslatinonal mechanism[J]. Cell,1986,47(6):921-928.
[219]Abreu,Maria T.Immunologic regulation of toll-like receptors in gut epithelium[J]. Gastroenterol,2003,19(6):559-564.
[220]Ponnappan S,Cullen SJ,Ponnappan U. Constitutive degradation of IκBαin human T lymphocytes is mediated by calpain[J].Immun Ageing,2005,2(4):15-23.
[221]吴礼国,甘华田.Rel/NF-κB信号传导通路与溃疡性结肠炎生物治疗策略的关系[J].国外医学·消化系疾病分册,2004,24(6):335-337.
[222]Hiscott J,Marois J,Garoufalis J,et al. Characterization of a functional NF-kappa B site in the human interleukin-10 promotor:evidence for a positive autoregulatory loop[J]. Mol Cell Biol,1993,13(10):6231-6240.
[223]Wang P,Wu P,Siegel MI,et al. Interleukin(IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes[J].J Biol Chem,1995,270(16):9558-9563.
[224]Cogswell PC,Scheinman RI,Baldwin AS. Promoter of the human NF-kappaB p50/p105 gene Regulation by NF-kappa B subunits and by C-Rel[J].J Immunol,1993,150(7):2794-2804.
[225]梁海清,李俊玲,王世和. NF-κB在溃疡性结肠炎中的作用[J].国际消化病杂志,2008,28(1):40-42.
[226]Ashwood P,Harvey R,Verjee T,et al. Funtional interactions between mucosal IL-1,IL-1ra and TGF-beta1 in ulcerative colitis[J]. Inflamm Res,2004,53(2):53-59.
[227]Sawa Y,Oshitani N,Adachi K,et al. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease [J].Int J Mol Med,2003,11(2):175-179.
[228]Abreu MT,Vora P,Fature E,et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide [J].J Immunol,2001,167(3):1609-1617.
[229]Kunsch C,Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter[J].Mol Cell Biol,1993,13(10):6137-6146.
[230]Lin R,Gewert D,Hiscott J. Differential transcriptional activation in vitro by NF-κB /Rel proteins[J].J Biol Chem,1995,270(7):3123-3131.
[231]Neurath MF,Pettersson S,Meyerzumbuschenfelde KH,et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice[J].Nat Med,1996,2(9):998-1004.
[232]Schottelins AJ,Baldwin AS. A role for transcription factor NF-kappaB in intestinal inflammation[J].Int J Colorectal Dis,1999,14(1):18-28.
[233]Kim JS,Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-κB signalling and gene expression by blockingκB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells[J].Immunology,2005,115(3):375-387.
[234]李军华,于皆平,何小飞,等.核因子-κB在大鼠实验性溃疡性结肠炎肠组织的表达及其意义[J].世界华人消化杂志,2003,11(2):214-218.
[235]Fogt F,Brown CA,Badizadegan K,et al. Low prevalence of loss of heterozy- gosity and SMAD4 mutations in sporadic and familial juvenile polyposis syndrome- associated juvenile polyps[J].Am J Gastroenterol,2004,99(10):2025-2031.
[236]Howe J R,Sayed MG,Ahmed AF,et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2,BMPR1B,and ACVR1 mutations [J].J Med Genet,2004,41(7):484-491.
[237]Elmali N,Baysal O,Harma A,et al. Effects of resveratrol in inflammatory arthritis[J]. Inflammation,2007,30(12):1-6.
[238]刘一品,李延青.核因子-κB的表达在溃疡性结肠炎发病机制中的意义[J].胃肠病学,2006,11(2):103-106.
[239]甘华田,欧阳钦,陈友琴,等.溃疡性结肠炎患者肠黏膜κ基因结合核因子的活化及抗炎药物的作用[J].中华医学杂志,2002,82(6):384-388.
[240]陈吉,高美丽,白晓茹,等.核因子-κB和细胞因子在溃疡性结肠炎中的表达及其意义[J].世界华人消化杂志,2009,17(2):209-212.
[2]邵丽黎.血竭四逆散治疗消化性溃疡50例[J].陕西中医,2003,24(1):17-18.
[3]刘德昭.四逆散加味治疗消化性溃疡40例[J].中国现代医生,2009,47(23):75-75,111.
[4]祁长虹,原培稼,郭爱则.四逆散加味治疗胆汁反流性胃炎30例临床观察[J].北京中医药大学学报,1997,20(3):68.
[5]杜曦.四逆散加味治疗慢性胃炎67例.浙江中西医结合杂志[J].2003,13(5):35-36.
[6]王华.慢性浅表性胃炎中医辨治临床探讨[J].中国现代药物应用,2010,4(1):117-118.
[7]姜周明.四逆散治疗胃肠运动障碍型功能性消化不良40例[J].中国中西医结合脾胃杂志,2000,8(4):251.
[8]薛红记.四逆散合六君子汤治疗功能性消化不良52例[J].中国中医药科技,2001,8(1):58.
[9]姜传田,马庭鑫.浅谈四逆散加减治疗功能性消化不良[J].中国中医药咨讯,2010,2(2):229.
[10]周向阳,王世勋,王荣林.四逆散为主辨证治疗肠易激综合征120例[J].国医论坛,1999,14(1):7.
[11]方杰.百合汤加四逆散治疗便秘型肠易激综合征36例[J].中国乡村医药,2009,16(5):53.
[12]杨洁.四君子汤配合四逆散治疗肠易激综合征临床研究[J].湖北中医杂志,2009,31(7):16-17.
[13]肖成.四逆散加味治疗慢性溃疡性结肠炎[J].内蒙古中医药,1998,17(1):26-27.
[14]张炜.四君子汤合四逆散加味治疗溃疡性结肠炎[J].成都中医药大学学报,2002,25(2):8-10.
[15]王如茂,胡开生.痛泻要方合四逆散加味治疗肝郁脾虚型溃疡性结肠炎58例[J].中医杂志,2008,24(5):438-439.
[16]扬大仁.四逆散加减治疗溃疡性结肠炎的体会[J].内蒙古中医药,2009,28(8):61.
[17]陶琳,肖旸,李帷,等.四逆散合左金丸联合雷贝拉唑治疗胃食管反流病36例[J].北京中医药,2009,28(10):785-787.
[18]刁喜凤,迟竹云.四逆散加味治疗肝脾曲结肠综合征28例[J].河南中医药学刊,1999,14(4):44-45.
[19]冯桂梅,张玉莲.四逆散加味治疗胃粘膜异型增生20例[J].长春中医学院学报,1998,14(2):15.
[20]刘海清,历淑芬,张俊杰,等.四逆散治便秘举隅[J].云南中医中药杂志,2009,30(7):42-43.
[21]龚时贤.茵惹四逆散治疗乙型肝炎42例[J].陕西中医,2001,22(7):400-401.
[22]刘星.加味四逆散抗拉米夫定停药后慢性乙型肝炎复发12例[J].中国中西医结合杂志,2002,22(8):593.
[23]王南.四逆散加减治疗慢性肝炎顽固性呃逆29例[J].实用中医内科杂志,2003,17(1):5.
[24]张天录,刘改莲,吴斌.加味四逆散治疗脂肪肝17例疗效观察[J].内蒙古中医药,1996,15(2):7.
[25]毛志远,王驰.四逆散合异功散治疗非酒精性脂肪肝3O例[J].浙江中医杂志,2009,44(6):429.
[26]刘亚军,王佳,王春生.加味四逆散治疗2型糖尿病脂肪肝肝损害临床观察[J].北京中医药,2009,28(7):530-531.
[27]王爱坚.四逆散为主治疗肝硬化腹水32例[J].山西中医,1999,15(2):34.
[28]孙守才,刘光炜.加味四逆散治疗慢性乙型肝炎肝纤维化的初步研究[J].陕西中医学院学报,2001,24(1):46-47.
[29]冯根凤,金朝辉,罗春香.四逆散加减治疗肝硬化肠源性内毒素血症体会[J].中国中医药信息杂志,2009,16(11):78.
[30]狄群英.四逆散加味治疗慢性胆囊炎54例[J].云南中医药杂志,1999,20,(1):23-24.
[31]卢艳晨.威金四逆散治疗慢性胆系疾患50例[J].陕西中医,2002,23(7):591.
[32]陈永敏.四逆散加味治疗慢性胆囊炎110例[J].中国中医药现代远程教育,2009,7(9):127.
[33]王如高,陈二军.补母实子法治疗难治性早搏32例[J].山西中医,1997, 13(3):55.
[34]杨洪军,孟繁蕴,孔立.四逆散加减治疗心脏神经官能症40例[J].浙江中医杂志,1998,33(4):155.
[35]雷健,丁红涛,吴艳霞.疏泄肝胆治疗冠心病心绞痛临床疗效分析[J].浙江中西医结合杂志,1998,8(2):93-94.
[36]杨永勤,李凤.四逆散加味治疗末梢神经炎25例[J].实用中医药杂志,2002,l8(11):28.
[37]薛汉荣,冷天文.黄连温胆汤合四逆散治疗失眠30例临床观察[J].江西中医药,2004,35(3):35.
[38]张帅.四逆散加味治疗2型糖尿病周围神经病变51例[J].中国中医药信息杂志,2008,15(9):56.
[39]张涛.四逆散加味治疗慢性血管紧张性头痛56例[J].中国医药指南,2009,7(10):77-78.
[40]杨晓晖.吕仁和教授运用四逆散治疗肾系疾病撮要[J].辽宁中医杂志,1996,23(9):387.
[41]杨红萍.四逆散加味治疗甲状腺机能亢进21例[J].实用中医药杂志,1996,3(4):14.
[42]郝小梅,刘梅.加味四逆散治疗痒咳42例[J].江西中医药,2009,40(7):18-19
[43]郑星宇,杜思哲,任林,等.四逆散合小青龙汤治疗哮喘急性发作期体会[J].浙江中医杂志,2010,45(2):111-112.
[44]巫嘉琴.四逆散合金铃子散治疗乳腺增生症88例[J].广西中医药,1998,21(6):29.
[45]白念兰,赵临浩.地肤子合四逆散加减治疗乳腺增生60例[J].中国民间疗法,2003,11(1):41.
[46]金锡蓉,杨胜强.四逆散加减治疗乳腺增生症55例[J].中国中医急症,2009,(8):1344.
[47]叶春娟.四逆散加味治疗盆腔炎48例[J].吉林中医药,2003,23(4):26.
[48]易蕾,黄梅,农夏欣,等.四逆散加味治疗慢性盆腔炎75例[J].江西中医药,2009,40(9):40-42.
[49]李艳萍,国亚利.四逆散合失笑散治疗原发性痛经80例[J].河北中医,1991,19(3):16-17.
[50]王晓萍,吴建红.金铃四逆散治疗痛经的临床观察与机理探讨[J].江西中医药,1998,29(2):18.
[51]姬淑琴.四逆散在妇科临床中的应用[J].山西中医,2000,16(2):50-51.
[52]贾思明,贾采云.益母石英四逆散加味治原发不孕[J].中国乡村医生,1998,14(11):39.
[53]张晓春.归肾丸合四逆散治疗排卵障碍性不孕症59例[J].山东中医杂志,2002,21(7):404-405.
[54]庞玉琴.四逆散加味治疗不孕症60例[J].陕西中医,2003,24(5):416-417.
[55]苏良溪.四逆散加味治疗前列腺肥大30例[J].福建医药杂志,1995, 17(6):200
[56]毛发勤.四逆散加味治疗阳痿54例[J].中国民间疗法,1999,7(6):28.
[57]陈柏莲.四逆散加味治疗不射精性不育症36例临床观察[J].北京中医,2000,19(1):40.
[58]蒋政余.四逆散加味治疗慢性附睾炎32例[J].湖南中医杂志,2001,17(2):29.
[59]庞宏永,杨曦,刘学伟.四逆散加味治疗精液不液化症36例[J].河北中医,2002,24(1):45.
[60]张伟宏,王君.四逆散加味治小儿厌食症64例[J].国医论坛,1996,11(5):16.
[61]詹雪梅,吴长明.四逆散加味治疗小儿腹痛58例[J].浙江中西医结合杂志,2000,10(5):62.
[62]王树红.四逆散加味治疗小儿发热54例临床观察[J].光明中医,2009,24(10):1909.
[63]吴辉,刘利萍.加味四逆散治疗小儿食积130例[J].福建中医药,2009,40(4):29-30.
[64]彭成,张磊,张利,等.四逆散治疗功能性消化不良的实验研究[J].成都中医药大学学报,1999,22(1):40-42.
[65]牛路芳,邱明义,石拓,等.四逆散治疗功能性消化不良的神经元及神经递质实验研究[J].时珍国医国药,2005,16(12):60-61.
[66]邓青秀,彭延娟,彭成,等.四逆散对肝郁证模型大鼠胃肠组织细胞形态及胃肠激素的影响[J].中国实验方剂学杂志,2007,13(6):33-36.
[67]王惠洁,杨蓉,林棋.四逆散和阿托品对离体兔肠平滑肌松弛作用的比较研究[J].山西中医学院学报,2006,7(5):20-21.
[68]李冀,毕辉,孙宇峰.四逆散抗实验性胃溃疡的药效学及作用机理研究[J].中华中医药学刊,2007,25(7):1317-1319.
[69]赵莹,王玉玫,丁淑霞,等.四逆散对大鼠胆汁流量的影响[J].中医药信息,2000,7(4):65-66.
[70]王东强,张国骏,史丽萍.四逆散对肝损害细胞bax基因表达的影响[J].天津中医药,2005,20(2):155-157.
[71]蒋洁云,徐强.四逆散及其各组成中药对实验性肝损伤的影响[J].中国天然药物,2004,2(1):46-50.
[72]金艳,王庆国,石任兵,等.四逆散活性成分对慢性应激诱导的抑郁症模型大鼠大脑皮层与海马5-HT(1A)受体mRNA表达的影响[J].北京中医药大学学报,2004,27(4):34-36.
[73]畅洪昇,王庆国,石任兵,等.四逆散活性成分对抑郁症大鼠慢性应激模型行为学及脑内单胺类神经递质的影响[J].北京中医药大学学报,2003,26(5):42-45.
[74]畅洪昇,梁吉春,孙建宁,等.四逆散有效部位对小鼠行为绝望和药物抑郁模型的作用[J].北京中医药大学学报,2006,29(7):451-453.
[75]畅洪昇,孙建宁,石任兵,等.四逆散有效部位对嗅球损毁大鼠海马细胞发生及CREB基因拷贝数量的影响[J].中国药学杂志,2006,41(14):1069-1071,1096.
[76]童瑶,邹军,倪力强,等.4种中药复方对大鼠实验性急性应激行为及下丘脑-垂体-肾上腺轴的影响[J].中国中药杂志,2005,30(23):1863-1866.
[77]童瑶,邹军,刘平,等.四种中药复方对急性心理应激大鼠IL-1β和IL-2的影响[J].上海中医药大学学报,2005,19(2):32-34.
[78]龚传美,管喜文,张军,等.四逆散对血粘度和甲襞微循环的作用[J].临床军医杂志,1991,19(4)9-11.
[79]龚传美,魏爱红,管喜文,等.四逆散对人、小白鼠微循环的影响[J].中药药理与临床,1991,7(2):6-7.
[80]刘珊珊,李廷利,朱维莉.四逆散对失眠大鼠睡眠时相的影响[J].中国医药导报,2008,5(15):19,36.
[81]李廷利,朱维莉,齐凤琴,等.四逆散催眠作用的实验研究[J].中医药信息,2004,21(1):59-60.
[82]李庆岚,齐云华,龚传美,等.四逆散抗VSV病毒和诱生干扰素的实验研究[J].中药药理与临床,1992,8(6):13-15.
[83]管喜文,龚传美,郑全清.四逆散抗疲劳作用实验观察[J].临床军医杂志,1992,20(3):9-10,8.
[84]李维,孔烈,于爽,等.四逆散对运动性疲劳大鼠海马突触素的调节作用[J].中国康复理论与实践,2009,15(8):739-741.
[85]龚传美,管希文,兰克信.四逆散的抗休克作用研究[J].中药药理与临床.1989,5(2):1-4.
[86]李岩,陈苏宁,李宇权,等.芍药甘草汤、四逆散对胃排空及小肠推进功能影响的拆方研究[J].中华消化杂志,1996,16(1)18-21.
[87]李强.四逆散对大鼠胃酸分泌、胃蛋白酶活性及预防应激性溃疡的基础研究[D].中国医科大学,硕士毕业论文,2002.
[88]郭际.四逆散有效成分提取和成分分析研究[D].成都中医药大学,硕士毕业论文,2002.
[89]韩向东,陈少丽,陈德兴,等.柴胡、白芍抗CCl4致实验性肝损伤的配伍规律研究[J].中国中医基础医学杂志,2005,11(8):593-594,598.
[90]李越峰,黄玉新,李廷利,等.四逆散拆方过程中成分变化的分析研究[J].中成药,2009,31(8):1308-1310.
[91]李军,石任兵,刘斌,等.四逆散不同配伍对甘草素和异甘草素煎出量的影响[J].北京中医药大学学报,2006,29(12):847-850.
[92]李军,石任兵,刘斌,等.四逆散不同配伍对柴胡皂苷a、b2及柴胡总皂苷煎出量的影响[J].北京中医药大学学报,2007,30(2):115-120.
[93]李军,姜华,石任兵,等.四逆散不同配伍对柴胡皂苷b1,h提取量的影响[J].中国中药杂志,2008,33(15):1912-1914.
[94]中华医学会消化病学分会.对炎症性肠病诊断治疗规范的建议(2000年)[J].现代实用医学,2003,15(10):656-659.
[95]Baumgart DC,Carding SR.Inflammatory bowel disease:cause and immunobiology [J]. Lancet,2007,369(9573):1627-1640.
[96]葛柳青,夏冰.炎症性肠病的基础研究与临床应用[J].中国处方药,2010,95(2):35-37.
[97]Bamias G,Nyce MR,De La Rue SA,eta1.New conception in the pathophysiology of inflammatory bowel disease[J].Ann Intern Med,2005,143(12):895-904.
[98]Ardizzone S, Porro GB. Comparative tolerability of therapies for ulcerative colitis[J]. Drug Saf,2002,25(8):561.
[99]吴国豪.肠道屏障功能[J].肠外与肠内营养,2004,11(1):44-47.
[100]赵树铭,康格非.前列腺素合酶-2的研究进展[J].国外医学临床生物化学与检验学分册,1998,19(4):103-106.
[101]毕涉,高骥授.炎症与抗炎症药物[M].北京:人民卫生出版社,1994:9,13-27,20-26.
[102]丁连安.肠屏障功能障碍[J].肠外与肠内营养,2005,12(1):55-58.
[103]田海河,董建华,田德录,等.中药治疗溃疡性结肠炎的临床及实验研究[J].北京中医药大学学报,1995,18(5):47-49.
[104]朱湘生,周泽泉,冯利君,等.消化系统疾病辨证与TXA2,PGI2的临床意义[J].中国中西医结合脾胃杂志,1998,6(3):172-173.
[105]张连峰,田曙光,王国新.溃疡性结肠炎患者血小板功能状态的研究[J].中国实用内科杂志,2000,20(2):98-99.
[106]方维丽.环氧合酶2和前列腺素在溃疡性结肠炎中的作用[J].中华内科杂志,2003,42(9):55.
[107]吴升华.脂氧素与白三烯研究进展[J].生理科学进展,1996,27(1):79-81.
[108]王晓兰.溃疡性结肠炎动物模型及研究进展[J].洛阳医专学报,2002,20(1):88-90.
[109]董梅,周喆，朱传樽.小儿炎症性肠病的研究进展[J].国外医学儿科学分册,1999,26(3):113-116.
[110]Kaufmann JA , Bickford PC , Taglialatela G.Free radical-dependent changes in constitutive Nuclear factor kappa B in the aged hippocampus[J].Neuroreport,2002,13(15):1917-1928.
[111]Nystrom T.The free-radical hypothesis of aging goes prok aryotic[J]. Cellular and molecular life sciences,2003,60(7):1333-1341.
[112]朱炳喜,吕愈敏.氧自由基在溃疡性结肠炎发病机制中的研究[J].中华消化内镜杂志,1997,14(2):40-41.
[113]马春曦,李志晋,詹丽英,等.溃疡性结肠炎大鼠肠组织中MDA、SOD、损伤指数的动态变化及其相关性研究[J].江西医学院学报,2005,45(3):4-6.
[114]张海燕,黄穗平,黄绍刚,等.清热祛湿法对实验性溃疡性结肠炎大鼠黏膜损伤的影响[J].时珍国医国药, 2010,21(2):354-356.
[115]吕永慧.溃疡性结肠炎的研究近况[J].中国中西医结合脾胃杂志,1996,4(2):116-119.
[116]张海燕,黄穗平,黄绍刚,等.清热祛湿法对实验性溃疡性结肠炎大鼠黏膜损伤的影响[J].时珍国医国药,2010年,21(2):354-356.
[117]黄俊,罗和生,李颖.大鼠实验性溃疡性结肠炎中NO、MDA、SOD的变化[J].武汉大学学报(医学版),2002,2(2):146-148.
[118]陈吉.一氧化氮与溃疡性结肠炎[J].世界华人消化杂志,2000,23(8):324-325.
[119]陈吉,吕愈敏,叶嗣懋,等.活动期溃疡性结肠炎与一氧化氮关系的临床研究[J].中华消化杂志,1998,18(5):295-297.
[120]陈垦,汤斌,祝斌,等.溃疡性结肠炎患者血清一氧化氮检测及意义[J].中国医师杂志,2002,4(10):1073-1074.
[121]崔淑华.解毒化瘀扶正中药对溃疡性结肠炎大鼠体内三种炎症介质的影响[D].河北医科大学,硕士毕业论文,2005.
[122]Rachmilewitz D,Eliakim R,Simon P,et al.Cytokines and platelet activating factor in human inflamed colonic mucosa[J].Agents Actions,1992,36(9):C32-36.
[123]许丽莉,王吉耀.活动期溃疡性结肠炎患者体内血小板激活状态的评价[J].中化消化杂志,2002,22(5):285-287.
[124]施昕,魏龙富,俞翁非,等.溃疡性结肠炎患者凝血功能改变[J].中华消化杂志,2002,22(4):6.
[125]李虹义,吴开春.血小板活化因子溃疡性结肠炎患者结肠粘膜的释放及其对结肠分泌的影响[J].医学信息,1996,9(12):30-31.
[126]Hawrelak JA,Myers SP.The causes of intestinal dysbiosis:a review[J].Altem Med Rev,2004,9(2):180-197.
[127]Kanauchi O,Mitsuyama K,Araki Y,et a1.Modification of intestinal flora in the treatment of inflammatory bowel disease[J].Curr Pharm Des,2003,9(4):333-346.
[128]刘力,张欢.肠道菌群失调与溃疡性结肠炎[J].现代中医药,2010,30(2):45-47
[129]李润美,韩英.肠道菌丛与炎症性肠病[J].现代消化及介入诊疗,2006,11(1):48-50.
[130]熊德鑫.现代微生态学[M].北京:中国科学技术出版社,2000,252-255.
[131]崔熠.溃疡性结肠炎患者结肠粘膜嗜酸性粒细胞和粪便菌群的研究[D].中南大学,硕士毕业论文,2009.
[132]Lim WC,Hanauer SB.Controversies with aminosalieylates in inflammatory bowel disease[J].Rev Gastroenterol Disord,2004,4(3):104-107.
[133]Laroux Fs,Pavliek KP,Wolf RE,et al.Dysregulation of intestinal mucosa immunity:implications in inflammatory bowel disease[J].News Physiol Sci,2001,16(6):272-277.
[134]夏冰.炎症性肠病的病因与发病机制[J].世界华人消化杂志,2001,9(3):245-250.
[135]Dasgupta A,Mandal A,Das M.Circulating immunoglobulin G1 antibody in patient with ulcerative colitis against the colonic epithelial protein detected by a novel monoelonal antibody[J].Gut,1994,35(12):1712-1717.
[136]Bach MA.The use of monoclonal anti-Tcell antibodies to study T cell inbalances in human disease[J].Clin Exp Im-munol,1981,45:449-456.
[137]王巧民,翟志敏.溃疡性结肠炎T淋巴细胞亚群检测及其意义[J].中华消化杂志,2002,22(6):366-367.
[138]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者T淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4):220-222.
[139]邓志波.溃疡性结肠炎外周血T淋巴细胞亚群的研究[J].河北医学,2006,10(8):675.
[140]Bhan AK,Mizoguchi E,SmithR N,et al.Colitis in transgenic and knockout animals as models of human inflammatory bowel disease[J].Immunol Rev,1999,169(1):195-207.
[141]Yoshizaki N,Sakamaki S,Takayanaki N,et al.Increased population of Th2 like cells with a phenotype of CD45RO+CD62L+ in patients with ulcerative colitis[J]. Gastroenterology,1998,suppl(4):G458.
[142]Lim WC,Hanauer SB.Controversies with aminosalicylates in inflammatory bowel disease[J].Rev Gastroenterol Disord,2004,4(3):104-107.
[143]De Jager PL,Franchimont D,Waliszewska A,et al.The role of the Toll receptor pathway insusceptibility to inflammatory bowel diseases[J].Genes Immun,2007,8(5):387-397.
[144]Abreu,Maria T.Immunologic regulation of toll-like receptors in gut epithelium[J]. Gastroenterol,2003,19(6):559-564.
[145]Sen R,Baltimore D.Indueibility of the immunoglobulin enhancer-binding Protein NF- kappa B by a posttranslatinonal mechanism[J].Cell,1986,47(6):921-928.
[146]Abreu MT,Vora P,Fature E,et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopoly saccharide[J].J Immunol,2001,167(3):1609-1617.
[147]Liu Y,Wang Y,Yamankuchi M,et al. Upregulation of Toll-like receptor gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is invoived in NF-κB activation[J]. Infection Immun,2001,69(5):2788-2796.
[148]田海河,李庆荣.中医药治疗溃疡性结肠炎思路方法的分析[J].中国中医药信息杂志,1995,2(9):23-24.
[149]陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4):11-12.
[150]王蕊.中医综合疗法治疗溃疡性结肠炎30例[J].湖北中医杂志,2005,27(12):23-24.
[151]王新月,田德禄.溃疡性结肠炎病因病理特点与中医辨治思路对策[J].北京中医药大学学报,2007,30(8):554-555.
[152]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-252.
[153]王向红,李佃贵,张金丽,等.“以方测证"验证化浊解毒对溃疡性结肠炎大鼠血清TNF-α、IL-1β的影响[J].现代中西医结合杂志,2010,19(9):1056-1057,1135.
[154]刘成高,饶群阳.陈光伟治疗慢性溃疡性结肠炎经验[J].实用中医药杂志,2004,20(2):88.
[155]徐王番,李守朝.培土抑木法在防治结肠炎中的应用[J].陕西中医,2006,27(12):1548-1549.
[156]王希利,彭艳红,孙明袜,等.溃疡性结肠炎以肺脾痰瘀论治研究[J].辽宁中医杂志,2007,34(6):747-748.
[157]田旭,白光.溃疡性结肠炎中医病因病机探要[J].实用中医内科杂志,2009,23(3):44-45.
[158]徐叔云,卞如濂,陈修.药理实验方法学[M].3版,北京:人民卫生出版社,2002:1335.
[159]李杨.溃疡性结肠炎动物模型的建立方法[J].中药新药与临床药理,1999,10(2):56-58.
[160]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通报,1998,14(4):86-88.
[161]朱峰,钱家鸣,潘国宗.细胞免疫反应性炎症性肠病动物模型的建立[J].中国医学科学院学报,1998,20(4):271-278.
[162]Tjandra K,Le T,Swain MG. Experimental colitis attenuates development of toxin- induced cholangitis in rats[J]. Digestive diseases and sciences,2002,47(6):1216-1223.
[163]Livard KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and 2-△△CT method[J]. Methods,2001,25(4):402-408.
[164]Wang T,Wang Y,Wu MC,et a1.Activating mechanism of transcriptor NF-Kappa B regulated by hepatitis B virus X protein hepatocellular carcinoma[J].World J Gastroenterol,2004,l0(3):356.
[165]国家药典委员会.中华人民共和国中药部颁标准(2010年版一部)[M].北京:中国医药科技出版社,2010:147,96.
[166]黄煌.张仲景50味药证[M].北京:人民卫生出版社,2008:85.
[167]YenMH,Lin CC,Yen CM.The immunomodulatory effectof saikosaponin derivatives and the root extract of Bupleurum kaoi in mice[J]. PhytotherRes,1995,9(4):351-358.
[168]梁云,崔若兰.柴胡皂甙及其同系物抗炎和免疫功能的研究进展[J].中国中西医结合杂志,1998,18(7):446-447.
[169]Kato M,Pu MY,Isobe KI,et al. Characterization of the immuno regulatory action of Saikosaponind[J].Cell Immunol,1994,159(1):15-17.
[170]王本祥.现代中药药理与临床[M].天津:天津科技翻译出版公司,2004:1242.
[171]王兴旺,陈敏珠,徐叔云.白芍总苷对T淋巴细胞亚群的作用[J].中国药理学通报,1992,8(5):340-344.
[172]李俊,梁君山,周爱武,等.白芍总甙对B淋巴细胞增殖和白介素-1生成的调节作用[J].中国药理学与毒理学杂志,1994,8(1):53-54.
[173]江苏新医学院.中药大辞典(下册)[M].上海:上海人民出版社,1977:1509-1510.
[174]Currier NL,Lejtenyi D,Miller SC.Effect over time of in-vivo administration of the polysaccharide arabinogalactan on immune and hemopoietic cell lineages in murine spleen and bone marrow[J].Phytomedicine,2003,10(2-3):145-153.
[175]李发胜,赵珏,池晓峰,等.甘草多糖对小鼠免疫调节作用的影响[J].中国中医药信息杂志,2009,16(6):35-36.
[176]Sung TS,La JH,Kim TW,et a1.Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat[J].J Veteri Sci,2006,7(2):143-150.
[177]Mc Alindon ME,Hawkey CJ,Mahida YR. Expression of interleukin 1βand interleukin 1βconverting enzyme by intestinal macrophages in health and inflammatory bowel disease[J].Gut,1998,42(2):214-219.
[178]马贵同,詹剑烈.中医中药治疗溃疡性结肠炎临床及实验研究[J].中医杂志,1985,26(7):33-35.
[179]Onderdonk AB,Steves RM,Cisneros RL,et a1.Adoptive transfer of immune enhancemcnt of experimental ulcerative colitis[J].Infect Immun,1984,46(1):64-67.
[180]邱绮玉,熊伍军,杨光,等.结肠宁对实验性溃疡性结肠炎的疗效观察[J].中国中西医结合脾胃杂志,1999,7(l):54-55.
[181]Jurius AR,Khoury NN,Reimund JM.Animal models of inflammatory bowel disease [J].J Pharmacol Toxicolog Methods,2004,50(2):81-92.
[182]Suzuki R,Kohno H,Sugie S,et a1.Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate induced colon carcinogenesis in mice[J].Carcinogenesis,2006,27(1):162-169.
[183]Rachimlewitz D,Stamler JS,Farmli F,et al.Peroxynitrite-induce rat colitis A new model of colonic inflammation[J].Gastroenterology,1993,105(6):1681-1688.
[184]黄永年,张元德,刑玉馥.大鼠溃疡性结肠炎模型的建立与观察[J].中华病理学杂志,1995,24(6):392.
[185]夏冰,黄梅芳,付苓.细胞免疫反应性溃疡性结肠炎模型[J].中华实验外科杂志,1992,9(3):130-131.
[186]任晋斌,许卫红,马文运,等.柳氮磺吡啶栓治疗实验性结肠炎的药效学研究[J].中国医药工业杂志,1993,24(9):408-410.
[187]Jewell DP.Ulcerative colitis,advances in medical treatment[M].Blackwell Scientiric Publ,1995,153.
[188]Morris GP,BecF PL,Herridge MS,et al.Hapten induced model of chronic inflanation and ulceration in the rat colon[J].Gastroenterology,1989,96(3):795-803.
[189]Podolsky DK.IBD:the dialectic of clinical advances and challenges[J].Dig Liver Dis,2005,37(1):1-2.
[190]Dohi T,Fujihashi K,Kiyono H,et al.Mice deficient in Th1-type and Th2-type cytokines develop distinct forms of hapten-induced colitis[J]. Gastroenterology,2000,119(3):724-733.
[191]Schreiber S,Heining T,Panzer U,et al.Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease[J]. Gastroenterology,1995,108(1):21-33.
[192]周天羽,张扬,王俊江,等.免疫复合法建立大鼠溃疡性结肠炎模型的研究[J].中医药学报,2005,33(6):23-24.
[193]江学良,权启镇,王东,等.复合法建立大鼠溃疡性结肠炎模型[J].青海医学院学报,1999,20(4):1-3.
[194]Rennick D,Davidson N,Berg D.Interleukin-10geneknock-outmice:a model of chronic inflammation[J].Clinical ImmunOlogy and Immunopathology,1995,76(3):S174-178.
[195]Ostanin,Pavlivk KP,Bharwani S,et a1.T cell induced inflammation of the small and large intestine in immunodeficient mice [J].Am J Physiol Gastrointest Liver Physiol,2006,290(1):G109-l19.
[196]Dieleman LA,Goerres MS,Arends A,et a1.Lactobacillus GG prevents recurrence ofcolitis in HLA-B27 transgenic rats after antibiotic treatment[J].GUT,2003,52(3):370-376.
[197]Aranda R,Sydora BC,McAllister PL,et a1.Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+,CD45RB high T cells to SCID recipients[J].J Immunol,1997,158(7):3464-3473.
[198]Madara JL,Podolsky DK,King NW,eta1.Characterization of spontaneous colitis in cotton-top tamarins ( saquinus oedipus ) and its response to sulfasalazine[J]. Gastroenterology,1985,88(1):13-19.
[199]Rogler G,Andus T. Cytokines in inflammatory bowel disease[J].World J Sung,1998,22(4):382-389.
[200]Manida YR,Wu K,Jewell DP. Enhanced production of Intericukin-1βin mononuclear cells isolated from mucosa with active ulcerative colitis and Crohn's disease[J].Gut,1989,30(6):835-838.
[201]Isaacs KL,Sartor RB,Haskill S.Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification[J]. Gastroenterology,1992,103(5):1587-1595.
[202]Ashwood P,Harvey R,Verjee T. Functional interactions between mucosal IL-l,IL-lraand TGF-beta 1 in ulcerative colitis[J].Inflamm Res,2004,53(2):53.
[203]Gan H,Ouvan Q,Jia D,et al. Activation of nuclear factor-kappaB and its relationship with cytokine gene expression in colonic mucosa of ulcerative colitis patients[J]. Zhonghua Nei Ke Za Zhi,2002,41(4):252-255.
[204]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的试验性研究[J].现代预防医学,2005,32(7):735-736.
[205]Sivakamar PV,Westric GM,Kanaly S,et al. Interleukin 18 is a primary mediator of the inflammatory associated with dextral sulphate sodium induced colitis-blocking interleukin 18 attenuates intestinal damage[J].Gut,2002,50(6):812,20.
[206]张可,邓长生,朱尤庆,等.溃疡性结肠炎组织中NF-κB,cox-2和iNOS表达的意义[J].世界华人消化杂志,2002,10(5):575-578.
[207]J F Mouser,Pham D,J S Hyams. Infliximab:a novel chimeric monoclonal antibody for the treatment of Crohn’Disease[J].Clinical Therapeutics,1999,21(6):932-942.
[208]祝斌,李巧勤,陈垦,等.溃疡性结肠炎患者周围血中性粒细胞凋亡与细胞因子水平的关系[J].临床消化病杂志,2003,15(6):254-256.
[209]Bonizzi G,Karin M. The two NF-kB activation pathways and their role in innate and adaptive immunity[J].Trends Immuno1,2004,25(6):280-288.
[210]朱萱萱,沈洪,施荣山,等.肠安胶囊治疗大鼠免疫性溃疡性结肠炎的实验研究[J].中国中医药科技,2002,9(1):19-21.
[211]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报(医学科学版),2001,28(4):330-333,375.
[212]Mosmann TR,Moore KW. The Role of IL-10 in Cross Regulation of Th1 and Th2 Responses[J].Immunology Today,1991,12(3):A49-53.
[213]Schreiber S,Heinig T,Thiele HG,et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease[J].Gastroenterology,1995,108(5):1434-1444.
[214]Cui HH,Chen CL,Wang JD,et al. Effect sofprobiotic on intestinal mucosa of patients with ulcerative colitis[J].World J Gastroentero,J 2004,10(10):1521-1525.
[215]许昌泰,郭学刚.溃疡性结肠炎与免疫因素[J].世界感染杂志,2004,4(6):524-526.
[216]Gustot T,Lemmers A,Louis E,et al. Profile of soluble cytokine receptors in Crohn’s disease[J].Gut,2005,54(4):488-495.
[217]Saniabadi AR,Hanai H,Suzuki Y,et al. Adacolumn for selective leukocyte-pheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy [J].J Clin Apher,2005,20(3):171-184.
[218]Sen R,Baltimore D. Indueibility of the immunoglobulin enhancer-binding Protein NF-Kappa B by a posttranslatinonal mechanism[J]. Cell,1986,47(6):921-928.
[219]Abreu,Maria T.Immunologic regulation of toll-like receptors in gut epithelium[J]. Gastroenterol,2003,19(6):559-564.
[220]Ponnappan S,Cullen SJ,Ponnappan U. Constitutive degradation of IκBαin human T lymphocytes is mediated by calpain[J].Immun Ageing,2005,2(4):15-23.
[221]吴礼国,甘华田.Rel/NF-κB信号传导通路与溃疡性结肠炎生物治疗策略的关系[J].国外医学·消化系疾病分册,2004,24(6):335-337.
[222]Hiscott J,Marois J,Garoufalis J,et al. Characterization of a functional NF-kappa B site in the human interleukin-10 promotor:evidence for a positive autoregulatory loop[J]. Mol Cell Biol,1993,13(10):6231-6240.
[223]Wang P,Wu P,Siegel MI,et al. Interleukin(IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes[J].J Biol Chem,1995,270(16):9558-9563.
[224]Cogswell PC,Scheinman RI,Baldwin AS. Promoter of the human NF-kappaB p50/p105 gene Regulation by NF-kappa B subunits and by C-Rel[J].J Immunol,1993,150(7):2794-2804.
[225]梁海清,李俊玲,王世和. NF-κB在溃疡性结肠炎中的作用[J].国际消化病杂志,2008,28(1):40-42.
[226]Ashwood P,Harvey R,Verjee T,et al. Funtional interactions between mucosal IL-1,IL-1ra and TGF-beta1 in ulcerative colitis[J]. Inflamm Res,2004,53(2):53-59.
[227]Sawa Y,Oshitani N,Adachi K,et al. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease [J].Int J Mol Med,2003,11(2):175-179.
[228]Abreu MT,Vora P,Fature E,et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide [J].J Immunol,2001,167(3):1609-1617.
[229]Kunsch C,Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter[J].Mol Cell Biol,1993,13(10):6137-6146.
[230]Lin R,Gewert D,Hiscott J. Differential transcriptional activation in vitro by NF-κB /Rel proteins[J].J Biol Chem,1995,270(7):3123-3131.
[231]Neurath MF,Pettersson S,Meyerzumbuschenfelde KH,et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice[J].Nat Med,1996,2(9):998-1004.
[232]Schottelins AJ,Baldwin AS. A role for transcription factor NF-kappaB in intestinal inflammation[J].Int J Colorectal Dis,1999,14(1):18-28.
[233]Kim JS,Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-κB signalling and gene expression by blockingκB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells[J].Immunology,2005,115(3):375-387.
[234]李军华,于皆平,何小飞,等.核因子-κB在大鼠实验性溃疡性结肠炎肠组织的表达及其意义[J].世界华人消化杂志,2003,11(2):214-218.
[235]Fogt F,Brown CA,Badizadegan K,et al. Low prevalence of loss of heterozy- gosity and SMAD4 mutations in sporadic and familial juvenile polyposis syndrome- associated juvenile polyps[J].Am J Gastroenterol,2004,99(10):2025-2031.
[236]Howe J R,Sayed MG,Ahmed AF,et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2,BMPR1B,and ACVR1 mutations [J].J Med Genet,2004,41(7):484-491.
[237]Elmali N,Baysal O,Harma A,et al. Effects of resveratrol in inflammatory arthritis[J]. Inflammation,2007,30(12):1-6.
[238]刘一品,李延青.核因子-κB的表达在溃疡性结肠炎发病机制中的意义[J].胃肠病学,2006,11(2):103-106.
[239]甘华田,欧阳钦,陈友琴,等.溃疡性结肠炎患者肠黏膜κ基因结合核因子的活化及抗炎药物的作用[J].中华医学杂志,2002,82(6):384-388.
[240]陈吉,高美丽,白晓茹,等.核因子-κB和细胞因子在溃疡性结肠炎中的表达及其意义[J].世界华人消化杂志,2009,17(2):209-212.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |